RT Journal Article
SR Electronic
T1 PD-1<sup>high</sup>CXCR5<sup>–</sup>CD4<sup>+</sup> Peripheral Helper T (Tph) cells Promote Tissue-Homing Plasmablasts in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.13.21253527
DO 10.1101/2021.03.13.21253527
A1 Asashima, Hiromitsu
A1 Mohanty, Subhasis
A1 Comi, Michela
A1 Ruff, William E.
A1 Hoehn, Kenneth B.
A1 Wong, Patrick
A1 Cohen, Inessa
A1 Coffey, Sarah
A1 Raddassi, Khadir
A1 Chaudhary, Omkar
A1 Unterman, Avraham
A1 Emu, Brinda
A1 Kleinstein, Steven H.
A1 Montgomery, Ruth R.
A1 Iwasaki, Akiko
A1 Cruz, Charles S. Dela
A1 Kaminski, Naftali
A1 Shaw, Albert C.
A1 Hafler, David A.
A1 Sumida, Tomokazu S.
YR 2021
UL http://medrxiv.org/content/early/2021/03/17/2021.03.13.21253527.abstract
AB A dysregulated immune response against coronavirus-2 (SARS-CoV-2) plays a critical role in the outcome of patients with coronavirus disease 2019 (COVID-19). A significant increase in circulating plasmablasts is characteristic of COVID-19 though the underlying mechanisms and its prognostic implications are not known. Here, we demonstrate that in the acute phase of COVID-19, activated PD-1highCXCR5−CD4+ T cells, peripheral helper T cells, (Tph) are significantly increased and promote inflammatory tissue-homing plasmablasts in patients with stable but not severe COVID-19. Analysis of scRNA-seq data revealed that plasmablasts in stable patients express higher levels of tissue-homing receptors including CXCR3. The increased Tph cells exhibited “B cell help” signatures similar to that of circulating T follicular helper (cTfh) cells and promoted B cell differentiation in vitro. Compared with cTfh cells, Tph cells produced more IFNγ, inducing tissue-homing chemokine receptors on plasmablasts. Finally, expansion of activated Tph cells was correlated with the frequency of CXCR3+ plasmablasts in the acute phase of patients with stable disease. Our results demonstrate a novel role for Tph cells in acute viral immunity by inducing ectopic, antibody secreting plasmablasts.Competing Interest StatementD.A.H. has received research funding from Bristol-Myers Squibb, Novartis, Sanofi, and Genentech. He has been a consultant for Bayer Pharmaceuticals, Bristol Myers Squibb, Compass Therapeutics, EMD Serono, Genentech, Juno therapeutics, Novartis Pharmaceuticals, Proclara Biosciences, Sage Therapeutics, and Sanofi Genzyme. Further information regarding funding is available on: https://openpaymentsdata.cms.gov/physician/166753/general-payments N.K. reports personal fees from Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, Indalo, Theravance, LifeMax, Three Lake Partners, RohBar in the last 36 months, and Equity in Pliant. N.K. is also a recipient of a grant from Veracyte and nonfinancial support from Miragen. In addition, N.K. has patents on New Therapies in Pulmonary Fibrosis and ARDS (unlicensed) and Peripheral Blood Gene Expression as biomarkers in IPF (licensed to biotech) all outside the submitted work. S.H.K. receives consulting fees from Northrop Grumman.Funding StatementThis study was supported by grants to D.A.H. from the National Institutes of Health (NIH) (U19 AI089992, R25 NS079193, P01 AI073748, U24 AI11867, R01 AI22220, UM 1HG009390, P01 AI039671, P50 CA121974, and R01 CA227473), the National Multiple Sclerosis Society (NMSS) (CA 1061- A-18 and RG-1802-30153), the Nancy Taylor Foundation for Chronic Diseases, and Erase MS (D.A.H); N.K. from NIH (R01HL127349, R01HL141852 and U01HL145567); K.B.H. and S.H.K. from NIH (R01AI104739); A.I. from NIH (R01AI157488 and R01NS111242) ; A.C.S. from NIH (K24AG042489). RNA sequencing service was conducted at Yale Center for Genome Analysis and Yale Stem Cell Center Genomics Core facility, the latter supported by the Connecticut Regenerative Medicine Research Fund and the Li Ka Shing Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board at the Yale School of Medicine (2000027291REG and FWA00002571, Protocol ID. 2000027690). Informed consent was obtained from all enrolled patients, healthcare workers and healthy donors.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe scRNA-seq and bulk RNA-seq data will be available before publication in a public repository. Flow cytometry data are available via ImmPort website (study ID; SDY1648, SDY1655). Data used to generate Figures are included in Supplemental Tables.